News
BOLT
4.275
+1.79%
0.075
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST), Revolution Medicines (RVMD) and Bolt Biotherapeutics (BOLT)
TipRanks · 1d ago
Weekly Report: what happened at BOLT last week (0615-0619)?
Weekly Report · 4d ago
Weekly Report: what happened at BOLT last week (0608-0612)?
Weekly Report · 06/15 09:30
Bolt Biotherapeutics Holds 2026 Annual Stockholder Meeting
TipRanks · 06/11 21:11
Bolt Biotherapeutics shareholders elect Quinn, Dupont to board class II seats
PUBT · 06/11 20:06
Weekly Report: what happened at BOLT last week (0601-0605)?
Weekly Report · 06/08 09:28
Weekly Report: what happened at BOLT last week (0525-0529)?
Weekly Report · 06/01 09:30
Bolt Biotherapeutics Initiated at Buy by Rodman & Renshaw
Dow Jones · 05/29 12:43
Bolt Biotherapeutics Price Target Announced at $22.00/Share by Rodman & Renshaw
Dow Jones · 05/29 12:43
Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22
Benzinga · 05/29 12:33
Bolt Biotherapeutics initiated with a Buy at Rodman & Renshaw
TipRanks · 05/28 20:58
Weekly Report: what happened at BOLT last week (0518-0522)?
Weekly Report · 05/25 09:31
Weekly Report: what happened at BOLT last week (0511-0515)?
Weekly Report · 05/18 09:31
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bolt Biotherapeutics (BOLT) and Upstream Bio, Inc. (UPB)
TipRanks · 05/13 17:10
Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Coherus Biosciences (CHRS)
TipRanks · 05/13 14:50
BRIEF-Bolt Biotherapeutics Reports First Quarter 2026 Financial Results
Reuters · 05/12 21:44
Bolt Biotherapeutics Q1 EPS $(4.31) Misses $(2.85) Estimate, Sales $26.000K Miss $1.500M Estimate
Benzinga · 05/12 21:19
Bolt Biotherapeutics GAAP EPS of -$4.31 misses by $1.46, revenue of $0.03M misses by $1.47M
Seeking Alpha · 05/12 20:53
Bolt Biotherapeutics Q1 revenue drops, net loss narrows
Reuters · 05/12 20:27
Bolt Biotherapeutics Q1 FY26 net loss narrows to $7.24 million; revenue drops to $26,000
PUBT · 05/12 20:12
More
Webull provides a variety of real-time BOLT stock news. You can receive the latest news about Bolt Biotherapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BOLT
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.